RegulatoryJul 6, 2026, 04:07 PM
Aligos Therapeutics' Pevifoscorvir Sodium Gets China Breakthrough Designation
AI Summary
Aligos Therapeutics announced that its drug candidate, pevifoscorvir sodium, received Breakthrough Therapy Designation from China's National Medical Products Administration (NMPA), making it eligible for priority review. This follows the company receiving a $25 million upfront payment from Xiamen Amoytop Biotech Co., Ltd. as part of an exclusive license deal for pevifoscorvir sodium in Greater China. Aligos is also eligible for up to $420 million in clinical, regulatory, and sales milestones, along with tiered royalties on net sales.
Key Highlights
- Pevifoscorvir sodium granted Breakthrough Therapy Designation in China.
- Received $25M upfront payment from Xiamen Amoytop Biotech Co., Ltd.
- Eligible for up to $420M in clinical, regulatory, and sales milestones.
- Aligos retains development and commercialization rights in US, Europe, South Korea, Japan.
- Amoytop plans to advance ALG-170675 into clinic in China in Q3 2026.
Price Impact
More from ALGS